{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:47:34Z","timestamp":1782200854231,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41397-026-00405-5","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:39:05Z","timestamp":1777034345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7466-4730","authenticated-orcid":false,"given":"Dani\u00ebl T.","family":"Coerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne Y.","family":"Smith-Apeldoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me C.","family":"Oude Nijhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1864-2151","authenticated-orcid":false,"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J.","family":"Tamminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien K. E.","family":"Veraart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-8447","authenticated-orcid":false,"given":"Jens H.","family":"van Dalfsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"405_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-90","volume":"9","author":"E Bromet","year":"2011","unstructured":"Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.","journal-title":"BMC Med"},{"key":"405_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"405_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","volume":"72","author":"J Kryst","year":"2020","unstructured":"Kryst J, Kawalec P, Mitoraj AM, Pilc A, Laso\u0144 W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72:543\u201362.","journal-title":"Pharmacol Rep"},{"key":"405_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","volume":"151","author":"Y Alnefeesi","year":"2022","unstructured":"Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693\u2013709.","journal-title":"J Psychiatr Res"},{"key":"405_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23:801\u201311.","journal-title":"Mol Psychiatry"},{"key":"405_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114892","volume":"197","author":"EM Hess","year":"2022","unstructured":"Hess EM, Riggs LM, Michaelides M, Gould TD. Mechanisms of ketamine and its metabolites as antidepressants. Biochem Pharmacol. 2022;197:114892.","journal-title":"Biochem Pharmacol"},{"key":"405_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","volume":"42","author":"LR Aleksandrova","year":"2021","unstructured":"Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42:929\u201342.","journal-title":"Trends Pharmacol Sci"},{"key":"405_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621\u201360.","journal-title":"Pharmacol Rev"},{"key":"405_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","volume":"264","author":"FS Correia-Melo","year":"2020","unstructured":"Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527\u201334.","journal-title":"J Affect Disord"},{"key":"405_CR10","first-page":"1186","volume":"87","author":"R Kohrs","year":"1998","unstructured":"Kohrs R, Durieux ME. Ketamine. Anesth Analg. 1998;87:1186\u201393.","journal-title":"Anesth Analg"},{"key":"405_CR11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","volume":"48","author":"N Zaki","year":"2023","unstructured":"Zaki N, Chen L, Lane R, Doherty T, Drevets WC, Morrison RL, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 2023;48:1225\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"405_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","volume":"9","author":"SY Smith-Apeldoorn","year":"2022","unstructured":"Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9:907\u201321.","journal-title":"Lancet Psychiatry"},{"key":"405_CR13","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1176\/appi.ps.201900625","volume":"71","author":"EL Ross","year":"2020","unstructured":"Ross EL, Soeteman DI. Cost-Effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatr Serv. 2020;71:988\u201397.","journal-title":"Psychiatr Serv"},{"key":"405_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jad.2022.09.083","volume":"319","author":"M Brendle","year":"2022","unstructured":"Brendle M, Robison R, Malone DC. Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. J Affect Disord. 2022;319:388\u201396.","journal-title":"J Affect Disord"},{"key":"405_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/15622975.2023.2169349","volume":"24","author":"S Meshkat","year":"2023","unstructured":"Meshkat S, Haikazian S, Di Vincenzo JD, Fancy F, Johnson D, Chen-Li D, et al. Oral ketamine for depression: an updated systematic review. World J Biol Psychiatry. 2023;24:545\u201357.","journal-title":"World J Biol Psychiatry"},{"key":"405_CR16","first-page":"19f12820","volume":"80","author":"C Andrade","year":"2019","unstructured":"Andrade C. Oral ketamine for depression, 1. J Clin Psychiatry. 2019;80:19f12820.","journal-title":"J Clin Psychiatry"},{"key":"405_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1192\/bjp.bp.115.165498","volume":"208","author":"RA Schoevers","year":"2016","unstructured":"Schoevers RA, Chaves TV, Balukova SM, Rot MaanH, Kortekaas R. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry. 2016;208:108\u201313.","journal-title":"Br J Psychiatry"},{"key":"405_CR18","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1038\/s41380-024-02478-9","volume":"29","author":"SY Smith-Apeldoorn","year":"2024","unstructured":"Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, Spijker J, van der Meij A, van Asselt ADI, et al. Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension. Mol Psychiatry. 2024;29:2657\u201365.","journal-title":"Mol Psychiatry"},{"key":"405_CR19","doi-asserted-by":"crossref","unstructured":"Veraart JKE, Smith-Apeldoorn SY, van der Meij A, Spijker J, Schoevers RA, Kamphuis J. Oral esketamine for patients with severe treatment-resistant depression: effectiveness, safety, and tolerability of a six-week open-label treatment program. J Psychopharmacol. 2025;39:559\u201370.","DOI":"10.1177\/02698811251332831"},{"key":"405_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-015-1826-y","volume":"71","author":"S Fanta","year":"2015","unstructured":"Fanta S, Kinnunen M, Backman JT, Kalso E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015;71:441\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"405_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1742-7843.2012.00908.x","volume":"111","author":"MA Peltoniemi","year":"2012","unstructured":"Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Kurkinen KJ, Neuvonen PJ, et al. Rifampicin has a profound effect on the pharmacokinetics of Oral S\u2010Ketamine and less on intravenous s\u2010ketamine. Basic Clin Pharmacol Toxicol. 2012;111:325\u201332.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"405_CR22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/biology12081055","volume":"12","author":"NY Davydova","year":"2023","unstructured":"Davydova NY, Hutner DA, Gaither KA, Singh DK, Prasad B, Davydov DR. High-Throughput assay of cytochrome P450-Dependent drug demethylation reactions and its use to re-evaluate the pathways of ketamine metabolism. Biology. 2023;12:1055.","journal-title":"Biology"},{"key":"405_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481\u20136.","journal-title":"Nature"},{"key":"405_CR24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/dmd.30.7.853","volume":"30","author":"Y Hijazi","year":"2002","unstructured":"Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853\u20138.","journal-title":"Drug Metab Dispos"},{"key":"405_CR25","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.2460\/ajvr.72.11.1505","volume":"72","author":"LD M\u00f6ssner","year":"2011","unstructured":"M\u00f6ssner LD, Schmitz A, Theurillat R, Thormann W, Mevissen M. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans. Am J Vet Res. 2011;72:1505\u201313.","journal-title":"Am J Vet Res"},{"key":"405_CR26","unstructured":"Flockhart DA, Thacker D, McDonald C, Desta Z. The Flockhart Cytochrome P450 Drug-Drug Interaction Table (Updated 2021). Division of Clinical Pharmacology, Indiana University School of Medicine. https:\/\/drug-interactions.medicine.iu.edu."},{"key":"405_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00228-012-1214-9","volume":"68","author":"MA Peltoniemi","year":"2012","unstructured":"Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT. S-ketamine concentrations are greatly increased by grapefruit juice. Eur J Clin Pharmacol. 2012;68:979\u201386.","journal-title":"Eur J Clin Pharmacol"},{"key":"405_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ejpain.2009.10.003","volume":"14","author":"NM Hagelberg","year":"2010","unstructured":"Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S\u2010ketamine. Eur J Pain. 2010;14:625\u20139.","journal-title":"Eur J Pain"},{"key":"405_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1472-8206.2011.00954.x","volume":"26","author":"MA Peltoniemi","year":"2012","unstructured":"Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT. St John\u2019s wort greatly decreases the plasma concentrations of oral S\u2010ketamine. Fundam Clin Pharmacol. 2012;26:743\u201350.","journal-title":"Fundam Clin Pharmacol"},{"key":"405_CR30","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1111\/bcp.15467","volume":"88","author":"IM Langmia","year":"2022","unstructured":"Langmia IM, Just KS, Yamoune S, M\u00fcller JP, Stingl JC. Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant \u2010 implications for precision dosing in a global perspective. Br J Clin Pharmacol. 2022;88:5149\u201365.","journal-title":"Br J Clin Pharmacol"},{"key":"405_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1515\/dmdi-2012-0027","volume":"27","author":"M Turpeinen","year":"2012","unstructured":"Turpeinen M, Zanger UM. Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metab Drug Interact. 2012;27:185\u201397.","journal-title":"Drug Metab Drug Interact"},{"key":"405_CR32","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1124\/dmd.113.051631","volume":"41","author":"Y Li","year":"2013","unstructured":"Li Y, Coller JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, et al. The CYP2B6*6 allele significantly alters the N-Demethylation of ketamine enantiomers in vitro. Drug Metab Dispos. 2013;41:1264\u201372.","journal-title":"Drug Metab Dispos"},{"key":"405_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/bcp.12614","volume":"80","author":"Y Li","year":"2015","unstructured":"Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, et al. CYP2B6*6 allele and age substantially reduce steady\u2010state ketamine clearance in chronic pain patients: impact on adverse effects. Br J Clin Pharmacol. 2015;80:276\u201384.","journal-title":"Br J Clin Pharmacol"},{"key":"405_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/mp.2012.42","volume":"18","author":"JC Stingl","year":"2013","unstructured":"Stingl JC, Brockm\u00f6ller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013;18:273\u201387.","journal-title":"Mol Psychiatry"},{"key":"405_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/02698811241238284","volume":"38","author":"NB Rodrigues","year":"2024","unstructured":"Rodrigues NB, Chen-Li D, Di Vincenzo JD, Juneja A, Pinder BD, McIntyre RS, et al. Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression. J Psychopharmacol. 2024;38:375\u201381.","journal-title":"J Psychopharmacol"},{"key":"405_CR36","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/ALN.0000000000001392","volume":"125","author":"LK Rao","year":"2016","unstructured":"Rao LK, Flaker AM, Friedel CC, Kharasch ED. Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance. Anesthesiology. 2016;125:1103\u201312.","journal-title":"Anesthesiology"},{"key":"405_CR37","doi-asserted-by":"publisher","first-page":"711943","DOI":"10.3389\/fgene.2021.711943","volume":"12","author":"TAM Mulder","year":"2021","unstructured":"Mulder TAM, van Eerden RAG, de With M, Elens L, Hesselink DA, Matic M, et al. CYP3A4\u221722 genotyping in clinical practice: ready for implementation? Front Genet. 2021;12:711943.","journal-title":"Front Genet"},{"key":"405_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12882-024-03467-4","volume":"25","author":"Z Li","year":"2024","unstructured":"Li Z, Wang X, Li D, Cheng S, Li Z, Guo H, et al. Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies. BMC Nephrol. 2024;25:48.","journal-title":"BMC Nephrol"},{"key":"405_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/08039488.2022.2065531","volume":"77","author":"VY Skryabin","year":"2023","unstructured":"Skryabin VY, Franck J, Lauschke VM, Zastrozhin MS, Shipitsyn VV, Bryun EA, et al. CYP3A4*22 and CYP3A5*3 impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. Nord J Psychiatry. 2023;77:73\u20136.","journal-title":"Nord J Psychiatry"},{"key":"405_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2174\/1389200218666170531112038","volume":"18","author":"O Lolodi","year":"2018","unstructured":"Lolodi O, Wang YM, Wright WC, Chen T. Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery. Curr Drug Metab. 2018;18:1095\u2013105.","journal-title":"Curr Drug Metab"},{"key":"405_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383\u201391.","journal-title":"Nat Genet"},{"key":"405_CR42","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","volume":"48","author":"RHN van Schaik","year":"2002","unstructured":"van Schaik RHN, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48:1668\u201371.","journal-title":"Clin Chem"},{"key":"405_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2359-1","volume":"19","author":"SY Smith-Apeldoorn","year":"2019","unstructured":"Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, van Asselt ADI, Touw DJ, aan het Rot M, et al. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. BMC Psychiatry. 2019;19:375.","journal-title":"BMC Psychiatry"},{"key":"405_CR44","first-page":"343","volume":"22","author":"J Levine","year":"1986","unstructured":"Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22:343\u201381.","journal-title":"Psychopharmacol Bull"},{"key":"405_CR45","unstructured":"IBM Corp. Released 2023. IBM SPSS Statistics for Windows, Version 29.0.2.0. Armonk, NY: IBM Corp"},{"key":"405_CR46","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40262-020-00953-4","volume":"60","author":"C Perez-Ruixo","year":"2021","unstructured":"Perez-Ruixo C, Rossenu S, Zannikos P, Nandy P, Singh J, Drevets WC, et al. Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression. Clin Pharmacokinet. 2021;60:501\u201316.","journal-title":"Clin Pharmacokinet"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00405-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00405-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00405-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:03:40Z","timestamp":1782198220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-026-00405-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1038\/s41397-026-00405-5","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JV has received speaker\u2019s fees from Janssen Pharmaceuticals, outside the submitted work. R.S. has received research funding for two randomised clinical trials with generic oral esketamine from the Netherlands Organisation for Health Research & Development and the National Health Care Institute, a speaker\u2019s fee and an investigator-initiated research grant from Janssen Pharmaceuticals, and consultancy fees from Clexio Biosciences, GH Research, Beckley PsyTech, and QPS. He has no financial relationships with commercial interests. DC, SS-A, JON, RvS, WT, DT, and JvD. declare to have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial protocol was approved by the Medical Ethics Review Committee of the University Medical Centre Groningen (approval number M16.198879). An independent Clinical Research Office and a Data Safety and Monitoring Board oversaw the study. Written informed consent was obtained for all participants. All methods were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}}],"article-number":"18"}}